Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Heron Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 70.1%. For fiscal 2025 it was 73.3%, against 73.2% the year before. The highest annual figure on record is 97.3% in fiscal 2016.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 73.3% | +0.1 |
| FY2024 | Dec 31, 2024 | 73.2% | +24.5 |
| FY2023 | Dec 31, 2023 | 48.8% | −0.3 |
| FY2022 | Dec 31, 2022 | 49.0% | +2.3 |
| FY2021 | Dec 31, 2021 | 46.7% | −12.5 |
| FY2020 | Dec 31, 2020 | 59.2% | +1.4 |
| FY2019 | Dec 31, 2019 | 57.8% | −6.7 |
| FY2018 | Dec 31, 2018 | 64.5% | −20.6 |
| FY2017 | Dec 31, 2017 | 85.1% | −12.2 |
| FY2016 | Dec 31, 2016 | 97.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 69.3% | −4.2 |
| Q1 FY2026 | Mar 31, 2026 | 69.4% | −8.9 |
| Q4 FY2025 | Dec 31, 2025 | 72.6% | −2.3 |
| Q3 FY2025 | Sep 30, 2025 | 68.8% | −2.4 |
| Q2 FY2025 | Jun 30, 2025 | 73.5% | +2.7 |
| Q1 FY2025 | Mar 31, 2025 | 78.3% | +2.6 |
| Q4 FY2024 | Dec 31, 2024 | 74.9% | +3.8 |
| Q3 FY2024 | Sep 30, 2024 | 71.2% | +29.1 |
| Q2 FY2024 | Jun 30, 2024 | 70.8% | +34.3 |
| Q1 FY2024 | Mar 31, 2024 | 75.6% | +32.6 |
| Q4 FY2023 | Dec 31, 2023 | 71.1% | +13.2 |
| Q3 FY2023 | Sep 30, 2023 | 42.1% | −2.5 |
| Q2 FY2023 | Jun 30, 2023 | 36.5% | −4.9 |
| Q1 FY2023 | Mar 31, 2023 | 43.1% | −8.5 |
| Q4 FY2022 | Dec 31, 2022 | 57.9% | +10.9 |
| Q3 FY2022 | Sep 30, 2022 | 44.6% | −6.6 |
| Q2 FY2022 | Jun 30, 2022 | 41.5% | +6.2 |
| Q1 FY2022 | Mar 31, 2022 | 51.6% | −2.4 |
| Q4 FY2021 | Dec 31, 2021 | 47.0% | −7.4 |
| Q3 FY2021 | Sep 30, 2021 | 51.1% | −13.0 |
| Q2 FY2021 | Jun 30, 2021 | 35.3% | −25.0 |
| Q1 FY2021 | Mar 31, 2021 | 54.0% | −4.2 |
| Q4 FY2020 | Dec 31, 2020 | 54.4% | −0.3 |
| Q3 FY2020 | Sep 30, 2020 | 64.1% | +4.4 |
| Q2 FY2020 | Jun 30, 2020 | 60.3% | −2.7 |
| Q1 FY2020 | Mar 31, 2020 | 58.2% | +5.5 |
| Q4 FY2019 | Dec 31, 2019 | 54.8% | −5.1 |
| Q3 FY2019 | Sep 30, 2019 | 59.7% | −2.1 |
| Q2 FY2019 | Jun 30, 2019 | 62.9% | −6.8 |
| Q1 FY2019 | Mar 31, 2019 | 52.7% | −20.3 |
| Q4 FY2018 | Dec 31, 2018 | 59.9% | −26.8 |
| Q3 FY2018 | Sep 30, 2018 | 61.7% | −26.0 |
| Q2 FY2018 | Jun 30, 2018 | 69.7% | −18.4 |
| Q1 FY2018 | Mar 31, 2018 | 72.9% | +5.6 |
| Q4 FY2017 | Dec 31, 2017 | 86.7% | −10.6 |
| Q3 FY2017 | Sep 30, 2017 | 87.7% | – |
| Q2 FY2017 | Jun 30, 2017 | 88.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 67.3% | – |
| Q4 FY2016 | Dec 31, 2016 | 97.3% | – |
See a number that looks wrong?